Lyceum Society April 2020
The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York
Established in 1993, The Lyceum Society is comprised of the Academy’s retired and semi-retired Members. These Members are from diverse backgrounds, have different areas of scientific interest and expertise, and have practiced many professions. Their disciplines include Biological and Biomedical Sciences, Chemical and Physical Sciences, Mathematics and Information Sciences, Social Sciences, Engineering, Medicine, Dentistry, and many others.
The Society hosts convivial monthly meetings at the Academy. These meetings feature lectures and discussions with scientists from around the world, and also provide participating Members with the opportunity to give self-directed presentations and seminars based on their own specialties or new research interests. All Academy Members are welcome.
All Lyceum meetings (except December) are Brown Bag lunches.
For more information about the Lyceum Society, click here.
April 06, 2020
Brown Bag Lunch
Communication has always faced the issue of reliability, from smudged ink, to the game of telephone, to weak radio signals, to errors in programs and data. The smallest digital error can stop a computer or crash a rocket. Yet all communications are subject to unwanted impulses called noise. Claude Shannon, founder of Information Theory, showed how Error Correction can overcome noise to produce the perfect copying that all digital technology requires. Today it is built into every device.
AI and Health Care
Historically, pharmaceutical invention has been driven by persistence, ingenuity and serendipity. Were it not for inspired scientists such as Stewart Adams, Gregory John Durant and Napoleone Ferrara game-changing medications such as ibuprofen (Advil), cimetidine (Tagamet) and bevacizumab (Avastin) might not have been discovered. The advent and uptake of artificial intelligence by the pharmaceutical industry has significantly expanded the team and the methodologies engaged in drug discovery and development. This now includes data scientists, computer scientists, information technology specialists and AI architects, often falling under the purview of research & development or even the chief information officer.
Artificial Intelligence (AI) is now being used in virtually if not every major healthcare function. This presentation will focus on AI as it applies to identifying new drug targets and compounds to engage them, innovations in clinical study design, patient recruitment, monitoring/pharmacovigilance and data collection and analysis. Disease diagnosis, both locally and remotely will also be considered as will cost implications and possible savings from incorporating AI in these processes.